AbbVie and Momenta announce Humira patent licence agreement

Biotech company Momenta has obtained the rights to use AbbVie’s Humira (adalimumab) IP, enabling the global commercialisation of Momenta’s proposed Humira biosimilar, M923.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AbbVie and Pfizer in Humira licensing deal

3 December 2018 AbbVie has granted Pfizer a non-exclusive global licence to its Humira IP, as announced on Friday, November 30.

Americas

AbbVie and Mylan agree Humira licensing deal

18 July 2018 US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

Americas

AbbVie and Samsung Bioepis resolve Humira litigation

9 April 2018 AbbVie has secured another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis.

More features

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

AbbVie and Momenta announce Humira patent licence agreement

More on this story

Editor's picks

Editor's picks

More features